< Back to previous page
Researcher
Isabelle Huys
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Responsible
From17 Dec 2020 → Today - Faculty of Law and Criminology (Faculty)
Member
From1 Oct 2014 → 30 Sep 2015 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today - Toxicology and Pharmacology (Division)
Member
From1 Oct 1999 → 9 Mar 2004
Projects
31 - 40 of 50
- Best-value biological medicine policy.From1 Jul 2019 → 31 Mar 2023Funding: National Office for Social Security
- Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generationFrom1 Apr 2019 → TodayFunding: H2020 - European Institute of Innovation and Technology
- European network staff eXchange for integrAting precision health in the health Care sysTemsFrom1 Mar 2019 → TodayFunding: H2020-EU.1.3.- EXCELLEN SCIENCE - Marie Skłodowska-Curie actions
- PhageBioticsFrom1 Jan 2019 → 31 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- How to reimburse and pay orphan drugs for rare diseases?From1 Jan 2019 → 31 Dec 2022Funding: FWO research project (including WEAVE projects)
- Balancing Innovation With Optimization in Oncology: Avenues for Bridging the Cancer Clinical Research GapFrom10 Oct 2018 → 12 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Do the EU and relevant national legal frameworks provide for a fair allocation of data control and responsibility in the context of precision medicine? A case study of clinical trialsFrom5 Oct 2018 → 31 Oct 2023Funding: FWO fellowships
- Unlocking Marine Genetic Resources: Streamlining the Legal, Policy and Business Aspects of the Marine Biodiscovery PipelineFrom21 Nov 2017 → 8 Sep 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Patient Preferences in Drug Development and Evaluation: Issues and RecommendationsFrom3 Oct 2016 → 20 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Patient Preferences in benefit risk assessments during the drug life cycleFrom1 Oct 2016 → 31 May 2022Funding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing, H2020 - European Institute of Innovation and Technology
Publications
1 - 10 of 213
- Testing and Practical Implementation of a User-Friendly Personalized and Long-Term Electronic Informed Consent Prototype in Clinical Research: Mixed Methods Study(2023)
Authors: David Geerts, Koen Yskout, Stef Verreydt, Pascal Borry, Liese Barbier, Isabelle Huys
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market Sustainability(2023)
Authors: Teresa Barcina Lacosta, Steven Simoens, Isabelle Huys
- A Belgian policy framework for best-value biological medicines(2023)
Authors: Yannick Vandenplas, Isabelle Huys, Steven Simoens, Arnold Vulto
- Balancing Innovation With Optimization in Oncology: Avenues for Bridging the Cancer Clinical Research Gap(2023)
Authors: Robbe Saesen, Isabelle Huys
- Cross-border clinical research in the EU: Fair allocation of data control and responsibility(2023)
Authors: Teodora Lalova-Spinks, Isabelle Huys, Peggy Valcke
- How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action(2023)
Authors: Rosanne Janssens, Liese Barbier, Elise Schoefs, Isabelle Huys
- The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis(2023)
Authors: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- Development of Cell and Gene Therapy Products: Implementation of a Blended Learning Approach(2023)
Authors: Isabelle Huys
Pages: 611 - 611 - Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments(2023)
Authors: Robbe Saesen, Isabelle Huys
- Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives(2023)
Authors: Rosanne Janssens, Elise Schoefs, Kristiaan Nackaerts, Isabelle Huys